Pharmacy facility
Legal Pressure Escalates as FDA Intensifies Crackdown on Direct-to-Consumer Pharma Advertising
FDA enforcement; direct-to-consumer advertising; pharmaceutical advertising crackdown; warning letters; legal challenges; AI monitoring; prescription drug ads; transparency in advertising; HHS; compounding pharmacies
Cigna’s Evernorth unveils 2 new programs aimed at GLP-1s
Programs – Publication Format, Glucagon-Like Peptide 1, Cigna ‘s, GLP-1s, Pharmacy facility, Enhance (action), Pharmaceutical Services
Compounding pharmacies dealt a blow in fight over end of semaglutide shortage
United States Food and Drug Administration, semaglutide, Compound, enforcement, Pharmacy facility, shortage, Wegovy
Eli Lilly Intervenes in Lawsuit to Block Compounded Versions of Tirzepatide Following FDA’s Shortage Resolution
Eli Lilly, tirzepatide, GLP-1 shortage, FDA, compounding pharmacies, lawsuit, Mounjaro, Zepbound
Supreme Court Declines to Review PhRMA’s Challenge to Arkansas’ 340B Contract Pharmacy Law
340B Program, Arkansas Act 1103, PhRMA, Supreme Court, Contract Pharmacies, Drug Pricing, Federal Preemption
Novo Nordisk Seeks FDA Ban on Compounded Semaglutide Formulations Amid Safety Concerns
Novo Nordisk, FDA, semaglutide, compounding pharmacies, safety concerns, GLP-1 medications, weight loss drugs, diabetes treatments
FDA Reconsiders Tirzepatide Shortage Status, Allowing Continued Compounding
Tirzepatide, FDA, drug shortage, compounding pharmacies, GLP-1 medications
FDA Reconsiders Removal of Eli Lilly’s Tirzepatide from Shortage List, Boosting Compounding Pharmacies
FDA, Eli Lilly, Tirzepatide, GLP-1 drug, Shortage list, Compounding pharmacies, Weight loss medication, Type 2 diabetes treatment
Compounding Pharmacies Challenge FDA’s Decision to End Eli Lilly’s GLP-1 Drug Shortage
Eli Lilly, GLP-1 drug, FDA, compounding pharmacies, drug shortage, lawsuit